Skip to main content

Bullous Pemphigoid

6
Pipeline Programs
9
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
5
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
4100%
+ 8 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Nihon Pharmaceutical
2 programs
1
1
NPB-01Phase 31 trial
NPB-01Phase 21 trial
Active Trials
NCT00809822Completed20Est. Oct 2010
NCT01408550Completed56Est. Sep 2013
Genentech
GenentechCA - Oceanside
2 programs
1
Azathioprine or Mycophenolate mofetilPhase 21 trial
OmalizumabPHASE_4Monoclonal Antibody1 trial
Active Trials
NCT00472030Completed2Est. Dec 2010
NCT00431119Completed70Est. Oct 2000
Dompé
DompéItaly - L'Aquila
1 program
1
DF2156APhase 21 trial
Active Trials
NCT01571895Terminated4Est. Jul 2012
Prevail Therapeutics
1 program
1
IxekizumabPhase 2Monoclonal Antibody
Sandoz
SandozAustria - Kundl
1 program
1
QGE031Phase 2
argenx
argenxBelgium - Zwijnaarde
2 programs
efgartigimod PH20 SCPHASE_2_31 trial
efgartigimod PH20 SCPHASE_31 trial
Active Trials
NCT05267600Completed98Est. Sep 2024
NCT05681481Terminated64Est. Mar 2025
Roche
RocheSTAVANGER NORWAY, Norway
1 program
Azathioprine or Mycophenolate mofetilPHASE_2
Regeneron
RegeneronTARRYTOWN, NY
1 program
dupilumabPHASE_2_3Monoclonal Antibody
Sanofi
SanofiPARIS, France
1 program
dupilumabPHASE_2_3Monoclonal Antibody1 trial
Active Trials
NCT04206553Completed106Est. Jan 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GenentechOmalizumab
argenxefgartigimod PH20 SC
Nihon PharmaceuticalNPB-01
argenxefgartigimod PH20 SC
Sanofidupilumab
DompéDF2156A
Nihon PharmaceuticalNPB-01
GenentechAzathioprine or Mycophenolate mofetil

Clinical Trials (8)

Total enrollment: 420 patients across 8 trials

NCT00472030GenentechOmalizumab

Efficacy and Safety of Omalizumab in Bullous Pemphigoid

Start: Aug 2007Est. completion: Dec 20102 patients
Phase 4Completed
NCT05681481argenxefgartigimod PH20 SC

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Start: Mar 2023Est. completion: Mar 202564 patients
Phase 3Terminated
NCT01408550Nihon PharmaceuticalNPB-01

Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids

Start: Aug 2011Est. completion: Sep 201356 patients
Phase 3Completed
NCT05267600argenxefgartigimod PH20 SC

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Start: Jun 2022Est. completion: Sep 202498 patients
Phase 2/3Completed
NCT04206553Sanofidupilumab

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

Start: Oct 2020Est. completion: Jan 2025106 patients
Phase 2/3Completed
NCT01571895DompéDF2156A

Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid

Start: Feb 2012Est. completion: Jul 20124 patients
Phase 2Terminated
NCT00809822Nihon PharmaceuticalNPB-01

Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.

Start: Nov 2008Est. completion: Oct 201020 patients
Phase 2Completed
NCT00431119GenentechAzathioprine or Mycophenolate mofetil

Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid

Start: Oct 1997Est. completion: Oct 200070 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.